Motley Fool Australia

Avita Therapeutics Inc (ASX: AVH) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Avita Therapeutics Inc (ASX: AVH) Latest News

most shorted ASX shares

Here are the 10 most shorted shares on the ASX

More »

3 asx shares to buy depicted by man holding up hand with 3 fingers up

These 3 ASX shares all posted massive gains today

More »

tiny asx share price growth represented by little girl looking surprised

2 small cap ASX shares growing at a rapid rate

More »

increase in asx medical software share price represented by doctor making excited hands up gesture

Leading broker names the ASX healthcare shares to buy in 2021

More »

finger selecting sad face from choice of happy, sad and neutral faces on screen

Why AVITA, IDP Education, Over the Wire, & Viva Energy shares are dropping lower

More »

Red wall with large white exclamation mark leaning against it

These are the 10 most shorted shares on the ASX

More »

ASX 200 weekly wrap represented by wooden block letters spelling out 'recap

ASX 200 Weekly Wrap: ASX hits new post-March high

More »

A stressed man with his hands on head trying to work out a major systems failure

These were the worst performing ASX 200 shares last week

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Avita Therapeutics Inc (ASX: AVH)

Avita Therapeutics Inc (ASX: AVH) is a medical technology company that specialises in regenerative medicine. Avita’s leading product, the RECELL System, was developed to address unmet medical needs in burns. The RECELL System is used to prepare ‘spray-on skin cells’ by using a small amount of the patient’s own skin. This is a revolutionary way to treat severe burns and significantly reduces the amount of donor skin required.

RECELL was granted US Food and Drug Administration (FDA) approval in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Since then, Avita has been undertaking studies to assess the use of the RECELL System in other applications. This includes the treatment of pediatric scald injuries, soft tissue reconstruction and vitiligo.

The Avita share price exploded in 2019, going from $0.081 to finish the year a phenomenal 696% higher at $0.645. With this, Avita earned itself a spot in the S&P/ASX 200 Index (ASX: XJO), as well as a place on many investors’ ASX watchlists.

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Sep 2020 Michael Perry Exercise 8 $60,000,004
02 Jun 2020 Michael Perry Issued 10 $4,843,940
02 Jun 2020 Michael Perry Exercise 10 $4,843,940
02 Jun 2020 Michael Perry Sell 4 $2,382,960
05 Mar 2020 Michael Perry Exercise 6 $4,350,057
05 Mar 2020 Michael Perry Issued 6 $4,350,057
05 Mar 2020 Michael Perry Sell 6 $3,995,008
03 Mar 2020 Michael Perry Exercise 6 $4,076,037
03 Mar 2020 Michael Perry Buy 6 $4,076,037
Show more


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Louis (Lou) James Panaccio Non-Executive Chairman,Non-Executive Director Jul 2014
Professor Suzanne Crowe Non-Executive Director Jan 2016
Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
Dr Michael S Perry Chief Executive Officer,Executive Director Feb 2013
Mr Louis Drapeau Non-Executive Director Jan 2016
Mr Mark Andrew Licciardo Company Secretary Mar 2018
Erin Liberto Chief Commercial Officer
David McIntyre Chief Financial Officer
Andrew Quick Chief Technology Officer
Mark Andrew Licciardo Company Secretary
Donna Shiroma General Counsel
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
Cede & Co 40,188,890 37.44%
HSBC Custody Nominees (Australia) Limited (I) 7,253,182 6.76%
Citicorp Nominees Pty Limited 7,045,639 6.56%
J P Morgan Nominees Australia Pty Limited 6,687,839 6.23%
National Nominees Limited 5,395,728 5.03%
Merrill Lynch (Australia) Nominees Pty Limited 1,816,130 1.69%
Mr Michael Perry 1,263,045 1.18%
HSBC Custody Nominees (Australia) Limited Gsco Eca 1,252,369 1.17%
Cs Fourth Nominees Pty Limited 1,097,835 1.02%
HSBC Custody Nominees (Australia) Limited (II) 735,579 0.69%
Ateq Investments Pty Ltd 590,000 0.55%
BNP Paribas Nominees Pty Ltd 490,104 0.46%
BNP Paribas Nominees Pty Ltd (I) 412,302 0.38%
Warbont Nominees Pty Ltd 403,116 0.38%
Brispot Nominees Pty Ltd 359,195 0.33%
Mr Adrian Simun Puljich 271,765 0.25%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 244,938 0.23%
Dibbens Developments Pty Limited 225,000 0.21%
Mr Anthony Mark Saia & Mrs Carmen Saia 217,500 0.20%
Citicorp Nominees Pty Limited (I) 213,979 0.20%
Show more

FAQ

Will Avita Medical pay a dividend in 2020?

Avita Therapeutics shares do not currently include a dividend payment. The company has made no announcements regarding paying a dividend in 2020.

Does Avita Medical offer a DRP?

No, Avita Therapeutics does not currently offer a dividend reinvestment plan (DRP).